



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Date: February 5, 2010

To: Primary Clinical Research Associates

From: Alicia Elsing
Research Protocol Specialist III

Re: N0821, A Phase II First-Line Study of a Combination of Pemetrexed, Carboplatin and Bevacizumab in Advanced Nonsquamous NSCLC Evaluating Efficacy and Tolerability in Elderly Patients (Age \geq 70 yrs) with Good Performance Status (PS $<$ 2)

The status change notice to temporarily close the study on October 30, 2009 has been revised. The actual temporary closure date was November 2, 2009. A revised status change notice has been posted to the web site. We apologize for any inconvenience this may have caused.

NOTE: This revised status change notice is being distributed as a FYI only as the study re-opened to patient accrual December 22, 2009.

If you have any questions, please feel free to contact me at elsing.alicia@mayo.edu or 507-538-3893.

Enclosure